


Cytokine storm potential of siRNA in human PBMCs and DCs

Toxicology & Applied Pharmacology


Travis Harrison, PhD Director, Immunology Services SRI International October 22, 2014

Overview

- Introduction
- Clinical Example
- Regulatory Guidance
- siRNA compounds
- Conclusions




Tisoncik, et al. Microbiol Molec Biol Rev. 2012. 76: 16-32.





Abbas et al. Pathologic Basis of Disease. 7th ed. Elsevier. 2005.

Cytokine Storm Causes

- Infection (viral, bacterial, protozoa)
 - Bacterial sepsis
 - Influenza
 - Ebola
- Immunomodulatory agents
 - Superantigens
 - TLR adjuvants
 - mAbs








Images: Wikimedia


Cytokine Storm Description



Takeda K and Akira S. Int. Immunol. 2005. 17:1-14

Cytokine Storm Characteristics

- Systemic inflammation
 - Increased endothelial permeability and capillary leakage
 - Fever
 - Hypotension and tachycardia
 - Fibrosis
- Clinical results
 - Edema
 - Hemorrhage
 - Organ damage
 - Death




Tracey. Nature Immunol. 2010. 11:561-564.

TGN1412 Dangers of Immunomodulators Revealed



- Monoclonal anti-CD28 Ab (superagonist)
- Intended for treatment of autoimmune disease by activating Treg

T cell Activation



Vasaturo et al. Front Immunol. 2013. 4:1-14.

TGN1412 Unexpected Outcome

- Performed preclinical safety studies in cynomolgus and rhesus monkeys
 - CD28 sequence homology nearly 100%
- No toxicity observed at 50 mg/kg
- Approval granted for Phase I clinical trial at 0.1 mg/kg
- Trial began March 2006
- 8 healthy volunteers (including 2 placebo)
 - Males aged 19-34
 - TGN1412 administered by i.v. infusion
- Symptoms began within 1 hour in all 6 people
 - Initial symptoms: Headache, vomiting, erythema
 - Progressive symptoms: Fever (39.5 to 40° C), hypotension, tachycardia, respiratory failure, multiple organ failure
 - 4 to 21 days in ICU
 - Increased cancer risk



TGN1412 Lessons learned

- Effector memory T cells demonstrated in vitro to play an important role
 - Cynomolgus and Rhesus monkey effector memory T cells do not express CD28
- In vitro cytokine release from PBMC required immobilized TGN1412
- Need to measure multiple cytokines because in vitro response may not be identical to in vivo
- Small increases in cytokines should not be dismissed
- More cautious approach to clinical trials when potential for cytokine storm exists

Guidance for Industry


Immunogenicity Assessment for Therapeutic Protein Products

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)

> August 2014 Clinical/Medical


Cytokine storm Regulatory guidance

- When risk of cytokine storm, start with lower dose than traditional calculations and infuse more slowly
- Animal studies useful only if compound is pharmacologically active
- Test a broad panel of cytokines
 - Minimally IL-2, IL-6, TNF- α and IFN- γ
- In vitro studies with human whole blood or PBMC
 - Cytokines, proliferation or other signs of activation
 - Signs of activation should indicate potential for cytokine storm even if no indication in preclinical studies



siRNA Therapeutics Background


- Interest in RNAi therapeutics has grown significantly in the past decade
- None have made it to market
- A few studies have been terminated



siRNA Therapeutics Lesson learned


- AGN211745 (Allergan)
 - siRNA specific for VEGF for treatment of age-related macular degeneration
 - Reached Phase II trial before termination
- Anti-angiogenic effect not sequence specific
 - TLR3
 - IFN- $\!\gamma$ and IL-12

Kleinman et al. Nature. 2008. 452:591-597




siRNA Therapeutics Modifications


Modifications increase stability and reduce immunogenicity





siRNA Evaluation Methods


- Topical anti-viral siRNAs
 - Unmodified
 - 2'-O-Methyl
 - 2'-Fluoro
- In vitro PBMC assay
 - Ficoll separation of PBMC isolated from healthy donors (n=3)
 - Incubation for 24 hr with siRNAs or controls
 - Cytokine panel measured by Luminex
- In vitro DC assay
 - CD14+ monocytes isolated from PBMC
 - Incubation for 5 days with IL-4 and GM-CSF to generate immature DCs
 - Incubation and cytokine analysis as above











siRNA Evaluation Cytokines (PBMC)

Cytokine(s)	Unmodified siRNA	2'O-Methyl (#1)	2'O-Methyl (#2)	2'-Fluoro
IL-6				
IL-8				
IL-10				
IL-12				
TNF-α				
IFN-γ, IL-1β, IL- 2, IL-4, IL-5, IL- 7, IL-13, GM- CSF				

siRNA Evaluation Cytokines (DC)

Cytokine(s)	Unmodified siRNA	2'O-Methyl (#1)	2'O-Methyl (#2)	2'-Fluoro
IL-6				
IL-8				
IL-10				
IL-12				
TNF-α				
IFN-γ, IL-1β, IL- 2, IL-4, IL-5, IL- 7, IL-13, GM- CSF				

Cytokine Storm Conclusions and Considerations

- Unmodified siRNA induced several cytokines in human PBMC
 - IL-6, IL-8, IL-10, IL-12, TNF-α
- Cytokine profile improved with siRNA modification
- No cytokines in monocyte-derived DC
 - IFN- α not part of panel
 - TLR3 expression also found on subsets of T, B, and NK cells
- Considerations
 - Larger number of donors to increase statistical power
 - PBMC vs whole blood
 - Cellular composition of blood differs from tissues

Acknowledgements

Jon Mirsalis, PhD

Nahoko Dunlap



Headquarters: Silicon Valley

SRI International 333 Ravenswood Avenue Menlo Park, CA 94025 650.859.2000

Washington, DC

SRI International 1100 Wilson Boulevard Arlington, VA 22209 703.524.2053

Harrisonburg, VA

SRI Shenandoah Valley 140 Research Drive Harrisonburg, VA 22802 540.438.6600

www.sri.com

www.sri.com/biosciences